



# newsletter

## In this issue

### Conference Listings

Click here



- **Editor's Review: Pick of the Papers from the third quarter of 2010**
- **EJC News**
- **New EJC special issue - Implementing cancer prevention in Europe**

We welcome any feedback on features you would like us to include in this newsletter. Please email Mustak Kothia: [m.kothia@elsevier.com](mailto:m.kothia@elsevier.com)



## Editor-in-Chief Announcement

### End of an era at EJC

December 2010 will mark the end of an era for the European Journal of Cancer. After 10 years at the helm, Professor John Smyth will retire as Editor-in-Chief.

Under Professor Smyth's leadership, the EJC has emerged as one of the leading, comprehensive oncology journals. Manuscript submissions have increased to more than 2,000 per year, whilst editorial times have remained rapid; online readership has grown steadily and by the end of 2010 we anticipate that more than 1 million articles will have been downloaded from the journal on ScienceDirect by readers from across the world; the Impact Factor increased five years in a row and now stands at more than 4.000. This progress is a testament to Professor Smyth's dedication to the EJC and to the hard work and commitment of his team of Editors.

Professor Jaap Verweij, Professor Maurizio D'Incalci, Dr Giovanna Damia, Professor John Kurtz and Professor Mike Stevens will also retire at the end of 2010. They have all served the EJC with distinction, showing commitment to the journal's authors and readers alike and the Publisher would like to take this opportunity to thank them for their dedication and hard work.

Professor Alexander (Lex) Eggermont has been appointed as Editor-in-Chief of the EJC, commencing his tenure as of January 2011. Professor Eggermont is the former Head of Surgery at Erasmus University in Rotterdam, The Netherlands. In October 2010 he became the Director of the Institut Gustave Roussy, Villejuif, France. He has a long association with the EORTC having served as President (2003 – 2006), Secretary General (1997-2000), and Chairman of the EORTC Clinical Research Report Division and the EORTC Melanoma Group (1994-2000). In addition, Professor Eggermont served as President of ECCO, the European Cancer Organisation, from 2007 to 2009, and is the current President of the European Academy of Cancer Sciences. He will be supported by a full team of Editors who will provide their expertise on experimental oncology, specific tumour-types, paediatric oncology, and epidemiology and prevention.

We would like to thank Professor Smyth and his team of Editors for their service and welcome Professor Eggermont as the Editor-in-Chief Elect for the EJC.

Sarah Jenkins  
Publisher, European Journal of Cancer  
Oxford, UK



Professor Smyth



Professor Eggermont



## Special Issue Announcement

### Implementing Cancer Prevention in Europe

Volume 46, Issue 14

#### Guest Editors:

Andrew G. Renehan, Isabelle Soerjomataram, Jose M. Martin-Moreno, Jan Willem Coebergh

The understanding of the risk factors underpinning the aetiology of many common cancers is well established, yet the conversion of this knowledge into prevention lags considerably behind. This special issue focuses on the translation of cancer epidemiology into public health policy, examining how social, political and environmental factors interact with one another during this transition.

Read the special issue online at: <http://www.sciencedirect.com/science/journal/09598049>



## Pick of the Papers

### Adjuvant chemotherapy in colon cancer - is it worth it?

Axel Grothey

Issue 46 (10) 1768-1769

This brief editorial by Axel Grothey from the Mayo Clinic is an excellent summary of the issues that we face in prescribing adjuvant chemotherapy for common cancers. Clearly only a small proportion of patients benefit whilst all accept toxicity, cost and inconvenience one way or another, and the issues are very well presented by Axel Grothey.

### The biology and treatment of EML4-ALK non-small cell lung cancer

Takaaki Sasaki et al

Issue 46 (10) 1773-1780

This paper by Sasaki and colleagues from Boston describes the importance of EML4 (echinoderm microtubule-associated protein-like 4) in relationship to lung cancer. The fusion between EML4 and ALK has been identified in an important subset of non-small cell lung cancers, since these are patients who have never smoked. There was much interest in this year's ASCO meeting in the clinical development of ALK inhibitors, now very relevant to the biology of EML4-ALK.

### Two decades at the cross-roads of biology, physics and epidemiology: Lessons learned in [18F]-FDG positron emission tomography in oncology.

Saiyada N F Rizvi et al

Issue 46 (12) 2150-2158

Despite all the obvious excitement about the development of PET imaging there is still major issues to resolve about the role of this technology in clinical practice. This excellent review from Rizvi and his colleagues from Amsterdam relates the biological and physical factors in PET scanning in relationship to the potential and limitations of this technology in clinical practice.

### Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference.

Daniel S-W Tan et al

Issue 46 (12) 2166-2177

The problem of both primary and acquired drug resistance is a very well recognised factor in cancer therapeutics. In this excellent paper from London the concept of understanding drug resistance mechanisms with modern genomic analyses is discussed in the context of improving the selection of patients for clinical trial and practice, to emphasis maximum therapeutic benefit and reduce inappropriate expenditure on ineffective therapy.

### Continuing medical education in Europe: Towards a harmonised system.

A Costa et al

Issue 46 (13) 2340-2343

One of the ironies of the rapid expansion of scientific knowledge in recent years is the difficulty of updating clinicians and scientists in a quality assured way. In this current perspective Alberto Costa and his colleagues provide an excellent resume of the challenges facing those providing continuing medical education in Europe.



## EJC Correspondence

Please click: <http://www.ecco-org.eu/News/News/EJC-Correspondence/Latest-Correspondence/page.aspx/910>

## Subscribe to EJC

2010 personal subscriptions are 18 print issues a year and online access (including back issues online) for just:

- 137 Euros for residents in European countries and Iran
- 96 Pounds sterling for UK residents
- 18,000 Yen for Japan
- 151 US Dollars for all countries except Europe, Japan and Iran



Elsevier 2010  
Published by Elsevier.  
EJC is the official journal of ECCO, EORTC, EACR,  
EUSOMA, ESO.

Impact factor 4.475 (2008)



THE LANCET Conferences  
HPV and Cancer  
Latest professional practice. Future clinical management  
November 12 - 13, 2010, Amsterdam, The Netherlands